SEC Form 4 · accession 0001209191-17-039655
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Jun 9, 2017
Accepted (ET)
Jun 13, 2017 · 6:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 9, 2017 | S | 15,000 | $15.015 | D | 319,083 | D | |
| Ordinary SharesF2 | Jun 12, 2017 | S | 5,956 | $15.082 | D | 313,127 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 9, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 15,000 shares in multiple trades at prices ranging from $15.00 to $15.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On June 12, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 5,956 shares in multiple trades at prices ranging from $15.00 to $15.225. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.